Bladder Cancer

Bladder Cancer Immunotherapy

Positive Results: Pembrolizumab and Chemotherapy Combo Improves Pathological Complete Response in High-Risk ER+/HER2- Breast Cancer Patients

1699024306_301023-TN23-Breast.png

Lung Cancer Bladder Cancer Breast Cancer CNS Cancers Colorectal Cancer COVID-19 Gastroesophageal Cancer Gastrointestinal Cancer Genomics/Genetics Geriatric Oncology Gynecologic Cancers Head and Neck Cancers Health-Care Policy Hepatobiliary Cancer Immunotherapy Integrative Oncology Kidney Cancer Legislation Leukemia Lymphoma Multiple Myeloma Neuroendocrine Tumors Palliative Care Pancreatic Cancer Prostate Cancer Sarcoma Skin Cancer Survivorship Symptom management Thyroid Cancer

FDA approval of bevacizumab biosimilar

1676463478_FDA-2.png

On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...

Latest Articles

Adjuvant in RCC
View More